

Avexa Limited

ABN 53 108 150 750

Appendix 4D

Half year report Period ending 31 December 2014

Results for announcement to the market

Operating performance:	
Revenue from ordinary activities	Up \$12,000 (100%) to \$12,000
Loss from ordinary activities after tax attributable to members	Loss decreased by \$753,000 (49%) to \$780,000
Loss for the period attributable to members	Loss decreased by \$753,000 (49%) to \$780,000
Dividends	
It is not proposed to pay dividends. There are no dividend or distribution reinvestment plans in operation and there has been no dividend or distribution payments during the financial half year ended 31 December 2014.	
No explanation considered necessary other than as provided within this report and in the Directors' Report for the half year ended 31 December 2014.	

Net tangible assets per ordinary security	Current period	Previous corresponding period to 31/12/13
Net tangible assets	11,251 in \$A'000	13,069 in \$A'000
Net assets	11,251 in \$A'000	13,069 in \$A'000
Issued share capital at reporting date	183,451 in \$A'000	183,455 in A'000
Number of shares on issue at reporting date	925,650,566	925,650,566
Net tangible assets per ordinary security	1.2 Cents	1.4 Cents
Net assets per ordinary security	1.2 cents	1.4 cents

Acquisitions and divestments

There have been no entities over which control has been gained or lost during the period ended 31 December 2014.

Associates and joint ventures

An equity interest of 30% is held in Coal Holdings USA LLC (CHUSA). Cash flows from this investment will contribute towards the funding of the AVX-305 Phase III clinical trial of apricitabine (ATC).

Accounting Standards

The financial report has been prepared in accordance with AASB134 Interim Financial Reporting and the Corporations Act 2001.

Auditors review report

The review report prepared by the independent auditor KPMG contains an emphasis of matter highlighting the existence of a material uncertainty that may cast significant doubt about the company's ability to continue as a going concern. The review report is attached hereto.